ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

ClinicalTrials.gov ID: NCT02409355

Public ClinicalTrials.gov record NCT02409355. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT02409355
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
8 participants

Conditions and interventions

Interventions

  • Atezolizumab Drug
  • Carboplatin Drug
  • Cisplatin Drug
  • Gemcitabine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 6, 2015
Primary completion
Dec 6, 2017
Completion
Dec 6, 2017
Last update posted
Feb 14, 2019

2015 – 2017

United States locations

U.S. sites
28
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
California Cancer Associates for Research & Excellence, Inc. Encinitas California 92008
Marin Cancer Care Inc Greenbrae California 94904
University of California San Diego La Jolla California 92093
Chao Family Comprehensive Cancer Center; UC Irvine Medical Center Orange California 92868
Eastern Connecticut Hematology and Oncology Associates; (ECHO) Norwich Connecticut 06360
Georgetown University Medical Center Washington D.C. District of Columbia 20007
Mount Sinai Medical Center Miami Beach Florida 33140
Florida Hospital Orlando Florida 32803
Straub Clinic & Hospital; Oncology Honolulu Hawaii 96813
Ingalls Memorial Hospital Harvey Illinois 60426
Consultants in Blood Disorders & Cancer Louisville Kentucky 40207
University of Maryland Baltimore Maryland 21201
Bay Hematology Oncology Easton Maryland 21601
Montana Cancer Specialists Missoula Montana 59802
Atlantic Health Cancer Center Summit New Jersey 07902
Maimonides Medical Center Brooklyn New York 11219
Montefiore Medical Center The Bronx New York 10467
Presbyterian Hospital Charlotte North Carolina 28204
Carolina Oncology Specialists, PA - Hickory Hickory North Carolina 28602
First Health of the Carolinas Pinehurst North Carolina 28374
Penn State Milton S. Hershey Medical Center Hershey Pennsylvania 17033
Spartanburg Regional Medical Center Spartanburg South Carolina 29303
Wellmont Cancer Institute Bristol Tennessee 37620
University Oncology Associates Chattanooga Tennessee 37403
Sarah Cannon Cancer Center Germantown Tennessee 38138
Vanderbilt Medical Center Nashville Tennessee 37232-7610
MultiCare Regional Cancer Center - Auburn Auburn Washington 98002-4117
West Virginia University Hospital Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02409355, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 14, 2019 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02409355 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →